Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...

Palisade Bio’s locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor, PALI-2108 receives Chinese patent: Carlsbad, California Monday, August 4, 2025, 16:00 Hrs ...

A sharp EV sales spike shows buyers scrambling to act before incentives disappear, while Hyundai enjoys record-setting ...

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, ...

The White River Alliance held its monthly meeting for July last week at the Heritage Culture Center in Meeker, where board ...

The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website ( palisadebio.com ).